Why the study?
Does quinapril compared to losartan improve the fibrinolytic system in patients with essential hypertension?
RCT (n=60)
Does quinapril compared to losartan improve the fibrinolytic system in patients with essential hypertension?
Quinapril and losartan have divergent effects on the fibrinolytic system in hypertensive patients, with quinapril enhancing and losartan attenuating fibrinolysis, likely mediated by changes in angiotensin II and IV concentrations.
Answers are grounded in this paper and cite their sources.
Divergent fibrinolytic effects should not yet change antihypertensive selection; leaves open class-specific thrombosis risk in hypertension.
To assess the effects of pharmacological interruption of the renin-angiotensin system on the fibrinolysis, tissue plasminogen activator antigen (t-PA), plasminogen activator inhibitor-1 antigens (PAI-1) and neurohormones, such as plasma renin activity, norepinephrine, angiotensin II (AII) and IV (AIV) concentrations, were measured in 60 hypertensives. Among them, 48 patients were divided into two groups (25 with 10-20 mg quinapril and 23 with 50-100 mg losartan) who received the drug for 6 months. AII had a weak positive correlation with free PAI-I (n = 60, r = 0.26, p < 0.05) whereas AIV had a strong positive correlation with free PAI-I (n = 60, r = 0.57, p < 0.0001). In both treatment groups, blood pressures were significantly reduced to similar levels after drug treatment. While plasma renin activity increased significantly in both groups after drug treatment, only the losartan group showed significant increases in AII and AIV concentrations. In the quinapril group, there was a significant change in t-PA (p < 0.001) without changes in PAI-1. In the losartan group, free PAI-I and total PAI-I (p < 0.05 for free PAI-I and p < 0.04 for total PAI-I) were significantly increased without a change in t-PA. Thus, quinapril enhanced fibrinolysis but losartan attenuated it. These unique effects of each drug on the fibrinolytic system appear to be associated with changes in AII and AIV concentrations.
No takes yet. Share an insight, caveat, or question.
Sakata et al. (2002) conducted an RCT in Essential Hypertension (n=60). Quinapril vs. Losartan was evaluated on Changes in tissue plasminogen activator antigen (t-PA) and plasminogen activator inhibitor-1 antigens (PAI-1).
Synapse has enriched 10 related papers. Consider them for comparative context: